- Advertisement -spot_img
Friday, February 3, 2023

Vaccine extends life for patients with aggressive brain cancer

  • 13% of people who get it in the UK live at least five years after diagnosis

  • People with the disease live an average of 12 to 18 months after diagnosis, some even less.

  • If approved, DCVax vaccine would be first new treatment in 17 years for patients with newly diagnosed glioblastoma

the world’s first vaccine for treat cancerous brain tumors opens up the possibility of offensive Extend patients’ lives by up to seven yearsAccording to a clinical trial published by The Guardian newspaper.

progress 2500 people can be benefited in a year In the UK those diagnosed with glioblastoma, the most common form of brain cancer and also one of the most aggressive, People with the disease live on average 12 to 18 months after diagnosisSome even fewer, but thanks to the vaccine, Nigel French, a study patient, survived. More than eight years after being diagnosed.

“The overall results are amazing”Says Professor Keyumer Ashkan, a neurosurgeon at King’s College London Hospital and the trial’s principal investigator. “Final results of this phase three trial Offer new hope to patients battling glioblastoma.”

Vaccination “It was shown to prolong life and, interestingly, in patients traditionally considered to have a poor prognosis”Like the big guys.

If the DCVax vaccine is approved, Will be the first new treatment in 17 years For newly diagnosed glioblastoma patients and for those who had a recurrence for the first time in 27 years.

Speaking in figures, newly diagnosed patients who received the vaccine survived an average of 19.3three more months, compared with 16.5 months for those receiving placebo treatment. Too, 13% of people who received it lived For at least five years after diagnosis.

How does the vaccine work?

“The vaccine works by stimulating the patient’s own immune system to fight the tumor of the patient It provides a personalized solution, working with the patient’s immune system, the most intelligent system known to man,” says Ashkan.

“The vaccine is produced combination of proteins from the patient’s own tumor with your white blood cells. This educates the white blood cells to recognize the tumor.”, explain the researchers. “When the vaccine is administered, these educated white blood cells Help the rest of the patient’s immune system To recognize the tumor as something that must be fought against and destroyed. It’s almost like training a sniffer dog.”

The vaccine is not yet available, but the US company that manufactures it, Northwest Biotherapeutics, plans to get approval and regulation as soon as possible to bring it to market.

World Nation News Desk
World Nation News Deskhttps://worldnationnews.com/
World Nation News is a digital news portal website. Which provides important and latest breaking news updates to our audience in an effective and efficient ways, like world’s top stories, entertainment, sports, technology and much more news.
Latest news
Related news
- Advertisement -


Please enter your comment!
Please enter your name here